Last reviewed 2026-04-20 · How we verify

Omicron-containing COVID-19 vaccine

The Omicron-containing COVID-19 vaccine, developed by Catholic Kwandong University, is currently marketed but lacks detailed revenue figures and primary trial results. A key strength is the patent protection extending to 2028, which helps maintain a competitive edge in the market. The primary risk is the lack of clear differentiation from other vaccines, as detailed comparative trial data is not provided.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• COVID-19 Booster Study in Healthy Adults in Australia (PHASE3)
• COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (PHASE2)
• Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial (PHASE3)
• Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
• Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (PHASE2, PHASE3)
• Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines (PHASE4)
• Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines (PHASE4)
• COVID-19 Fourth Dose Study in Australia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Omicron-containing COVID-19 vaccine CI brief — competitive landscape report
• Omicron-containing COVID-19 vaccine updates RSS · CI watch RSS
• Catholic Kwandong University portfolio CI